MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers

British Journal of Neurosurgery

Volumn 27, Issue 6, 2013, Pages 772-778

  Gutenberg, A ^a,b   Bock, H C ^a   Bruck W ^a   Doerner, L ^c   Mehdorn, H M ^c   Roggendorf, W ^d   Westphal, M ^e   Felsberg, J ^f   Reifenberger, G ^f   Giese, A ^a,b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c UNIVERSITY OF KIEL   (Germany)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e UNIVERSITY OF HAMBURG   (Germany)

^f HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

BCNU; BCNU wafer; Gliadel ; Glioblastoma; MGMT methylation; Temozolomide

Indexed keywords

CARMUSTINE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ARTICLE; BRAIN ABSCESS; BRAIN EDEMA; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; GLIOBLASTOMA; HUMAN; HYDROCEPHALUS; LEUKOPENIA; MALE; MENINGITIS; METHYLATION; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; RECURRENT CANCER; SEIZURE; THROMBOCYTOPENIA; WOUND HEALING; WOUND INFECTION;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARMUSTINE; CHEMORADIOTHERAPY; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE-FREE SURVIVAL; DNA METHYLATION; FEMALE; GLIOBLASTOMA; HUMANS; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PROGNOSIS; PROMOTER REGIONS, GENETIC; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84889590020     PISSN: 02688697     EISSN: 1360046X     Source Type: Journal    
DOI: 10.3109/02688697.2013.791664     Document Type: Article

References (29)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-96.
2. Denny BJ, Wheelhouse RT, Stevens MF, et al. NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry 1994; 33: 9045-51.
3. Kaina B, Margison G P, Christmann M. Targeting O-methylguanine-DNA methyltransferase with specifi c inhibitors as a strategy in cancer therapy. Cell Mol Life Sci 2010; 67: 3663-81.
4. Tolcher AW, Gerson SL, Denis L, et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 2003; 88: 1004-11.
5. Wick A, Felsberg J, Steinbach JP, et al. Effi cacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 2007; 25: 3357-61.
6. Yamauchi T, Ogawa M, Ueda T. Carmustine-resistant cancer cells are sensitized to temozolomide as a result of enhanced mismatch repair during the development of carmustine resistance. Mol Pharmacol 2008; 74: 82-91.
7. Brem H, Ewend MG, Piantadosi S, et al. The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial. J Neurooncol 1995; 26: 111-123.
8. Brem H, Piantadosi S, Burger P C, et al. Placebo-controlled trial of safety and effi cacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 1995; 345: 1008-12.
9. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 2003; 5: 79-88.
10. Westphal M, Ram Z, Riddle V, et al. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien) 2006; 148: 269-75; discussion 275.
11. Smith KA, Ashby LS, Gonzalez LF, et al. Prospective trial of gross-total resection with Gliadel wafers followed by early postoperative Gamma Knife radiosurgery and conformal fractionated radiotherapy as the initial treatment for patients with radiographically suspected, newly diagnosed glioblastoma multiforme. J Neurosurg 2008; 109 Suppl: 106-117.
12. Noel G, Schott R, Froelich S, et al. Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (Carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas. Int J Radiat Oncol Biol Phys 2011; 82: 749-755.
13. Olson JJ, McKenzie E, Skurski-Martin M, et al. Phase I analysis of BCNU-impregnated biodegradable polymer wafers followed by systemic interferon alfa-2b in adults with recurrent glioblastoma multiforme. J Neurooncol 2008; 90: 293-99.
14. Metellus P, Coulibaly B, Nanni I, et al. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort. Cancer 2009; 115: 4783-94.
15. Macdonald DR, Cascino TL, Schold SC Jr, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8: 1277-80.
16. Felsberg J, Rapp M, Loeser S, et al. Prognostic signifi cance of molecular markers and extent of resection in primary glioblastoma patients. Clin Cancer Res 2009; 15: 6683-93.
17. Stupp R, Hegi ME, van den Bent MJ, et al. Changing paradigms-an update on the multidisciplinary management of malignant glioma. Oncologist 2006; 11: 165-80.
18. Garside R, Pitt M, Anderson R, et al. The effectiveness and costeffectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Health Technol Assess 2007; 11: iii-iv, ix-221.
19. Khan MK, Hunter GK, Vogelbaum M, et al. Evidence-based adjuvant therapy for gliomas: current concepts and newer developments. Indian J Cancer 2009; 46: 96-107.
20. McGirt MJ, Th an KD, Weingart JD, et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg 2009; 110: 583-8.
21. Sampath P, Brem H. Implantable slow-release chemotherapeutic polymers for the treatment of malignant brain tumors. Cancer Control 1998; 5: 130-7.
22. Fleming AB, Saltzman WM. Pharmacokinetics of the carmustine implant. Clin Pharmacokinet 2002; 41: 403-19.
23. Gilbert MR, Wang M, Aldape KD, et a l. RTOG 0525: A randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM). J Clin Oncol 2011; 29.
24. Glas M, Happold C, Rieger J, et al. Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. J Clin Oncol 2009; 27: 1257-61.
25. Quinn JA, Desjardins A, Weingart J, et al. Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 2005; 23: 7178-87.
26. Brem H, Mahaley MS Jr, Vick NA, et al. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg 1991; 74: 441-6.
27. Sabel M, Giese A. Safety profi le of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience. Curr Med Res Opin 2008; 24: 3239-57.
28. Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience. Neurosurg Rev 2010; 33: 441-9.
29. Giese A, Bock HC, Kantelhardt SR, et al. Risk management in the treatment of malignant gliomas with BCNU wafer implants. Cen Eur Neurosurg 2010; 71: 199-206.